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Figure 1: Flow diagram showing the stages of HCV infection for naive PWID (i = 0)
and experienced PWID (i = 1). The arrows in the diagram indicate the possi-
ble transitions for PWID between stages of HCV infection and the parameters
shown are the per capita rate of flow between the stages. The rate at which PWID
join and leave the population (µ) and the rate that PWID progress from the naive
tier to the experienced tier (η) are not shown.
Figure 2: Parameter plot for the high prevalence setting. This plot shows the chronic
HCV transmission probability values required to achieve an endemic HCV preva-
lence of 67% (lower 95% CI estimate, αyF = 0.166%), 70% (central estimate,
αyF = 0.193%) and 73% (upper 95% CI estimate, αyF = 0.225%).
Figure 3: Results of sensitivity analyses for the high prevalence setting. For each sce-
nario, the figure shows the HCV transmission probability through paraphernalia
sharing with chronic cases which results in a HCV prevalence of 70%. The solid
vertical line indicates the central estimate obtained using the baseline parameter
estimates. The starred points indicate the three scenarios that lead to changes in
the HCV transmission probability (through paraphernalia sharing) by a margin
of more than 0.09%. Note for brevity we have used ns to denote needle/syringe.
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Abstract
Background
In order to prevent the spread of the hepatitis C virus (HCV) amongst people who
inject drugs (PWID), it is imperative that any injecting risk behaviour which may con-
tribute to the transmission of disease has its role quantified. To inform public health or-
ganisations, mathematical modelling techniques were used to explore the risk of HCV
infection through the sharing of injecting paraphernalia (including filters, cookers and
water).
Methods
A mathematical model was developed for the spread of HCV based on the inject-
ing behaviour of PWID in Scotland, with transmission occurring through the sharing of
needles/syringes and other injecting paraphernalia. Numerical simulations were used
to estimate the transmission probability for HCV through the sharing of injecting para-
phernalia such that the modelled endemic HCV prevalence fitted with that observed
amongst PWID in Scotland.
Results
The transmission probability of HCV through injecting paraphernalia was mod-
elled to be over 8 times lower than that through needles/syringes (approximately 0.19%-
0.30% and 2.5%, respectively), assuming transmission occurs through a combination
of at least filters and cookers. In the context of reported needle/syringe and parapher-
nalia sharing rates in Scotland, it is estimated that 38% and 62% of HCV infections
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are contributed by these practices, respectively. If needle/syringe sharing rates were to
be twice those reported, the contributions would be 70% and 30%, respectively.
Conclusion
Given that the sharing of injecting paraphernalia among PWID is common, HCV
transmission through this route could be contributing to the growing healthcare burden
associated with this chronic disease. Every effort should therefore be made to establish
(a) the contribution that paraphernalia sharing is making to the spread of HCV, and (b)
the effectiveness of services providing sterile paraphernalia in preventing infection.
Keywords: hepatitis C, HCV, PWID, needle and syringe sharing, injecting
paraphernalia, mathematical modelling
1. Introduction
The hepatitis C virus (HCV) is a major health concern for the 16 million (range
11-21 million) people who inject drugs (PWID) worldwide (Mathers et al., 2008). Ex-
trapolated estimates from a systematic review of global HCV prevalence suggests that
10 million (range 6-15 million) PWID are estimated to be infected with HCV; which
is 3.5 times the number of PWID who are infected with HIV (Nelson et al., 2011).
The sharing of contaminated needles/syringes is considered to have the greatest role
in HCV transmission (Thorpe et al., 2002; Bialek and Terrault, 2006) among PWID.
However, PWID also share other injecting paraphernalia (such as cookers/spoons, fil-
ters and water) in the process of preparing drugs for injection, and they do so at greater
frequency than that with which they share needles/syringes (Koester, 1996; Speed,
1998; Gaskin et al., 2000; Needle Exchange Surveillance Initiative, 2010). There is
now laboratory and epidemiological evidence to suggest that the re-use of drug prepa-
ration equipment may be another source of HCV transmission.
In terms of laboratory studies, Crofts et al. (2000) found that it was possible to
detect HCV RNA on items other than needles/syringes, including swabs (in 6 out of
9 items tested), filters (in 2/5), water samples (in 1/3) and spoons (in 1/4). Thibault
et al. (2011) recently detected the presence of HCV RNA in 80% of swabs (in 4/5
pools tested, involving pools of ten items) and 50% of cups (in 1/2 pools tested) from
suspected HCV infected PWID; HCV RNA was not detected among pools of used
filters and water vials, but only a few were tested. In terms of epidemiological stud-
ies, De et al. (2008) identified ten studies that had examined HCV incidence and the
sharing of injecting paraphernalia, reporting relative risks of infection associated with
paraphernalia between two and six (although with wide uncertainty in these estimates).
Furthermore, a meta-analysis of 8 studies, conducted by Pouget et al. (2012), recently
reported that the pooled risk ratio of HCV seroconversion associated with the shar-
ing of drug preparation equipment (excluding syringes) was similar to that for syringe
sharing (2.2, 95% CI 1.3-3.9 and 2.0, 95% CI 1.6-2.5, respectively).
Previous modelling work in Scotland estimated that several thousand HCV infec-
tions had potentially been prevented as a consequence of reduced needle/syringe shar-
ing rates during the late 1990s and 2000s (compared to those in the late 1980s and
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early 1990s), most likely as a result of harm reduction measures (Hutchinson et al.,
2006). The prevalence of HCV among PWID in Scotland however remains high (with
over half the population estimated to be infected), despite reported low levels of nee-
dle/syringe sharing (Needle Exchange Surveillance Initiative, 2008, 2010). In contrast,
much higher levels of paraphernalia sharing are reported: 48% and 15% report shar-
ing paraphernalia and needles/syringes in the past six months, respectively, (Needle
Exchange Surveillance Initiative, 2010). Taking this and other available evidence into
account, recently developed Scottish guidelines for services providing injecting equip-
ment recommend that paraphernalia items - including cookers, filters and water - are
made available, and that “these items be supplied in sufficient quantities to enable the
use of one item each per injection” (Scottish Government, 2008, 2010).
Understanding the role that paraphernalia plays in disease transmission is funda-
mental to the planning and development of HCV prevention services. Rates of HCV
infection following needle-stick injury among healthcare workers have demonstrated
the risk of transmission through re-use of contaminated needles/syringes (Centre for
Disease Control, 2001); comparable evidence does not, however, exist in relation to
paraphernalia. This analysis therefore represents a first attempt to estimate the proba-
bility of HCV transmission through paraphernalia sharing.
2. Methods
2.1. Model description
We have developed a dynamic mathematical model which allows HCV to be trans-
mitted in a PWID population through the sharing of used needles/syringes and para-
phernalia items (described below); the mathematical design and equations have been
described elsewhere (Corson et al., 2012a,b) and are presented in brief in the supple-
mentary material.
We assume that the population is of size n, where n is large and constant. PWID
leave the population - either due to death or permanent cessation of injecting - at a per
capita rate µ and are immediately replaced by PWID susceptible to HCV infection.
The PWID population is divided into those susceptible to HCV infection (denoted
by x for those previously uninfected and x1 for those previously infected), those who
have acute HCV infection (h1 and h2), those who have developed chronic HCV infec-
tion (y) and those who are immune to HCV re-infection (z) (Figure 1).
Once infected with HCV, susceptible PWID progress to an acute stage of infection
(either h1 or h2). We assume that a proportion (δ ) of these infected PWID progress to
the acute h2 infected class; these individuals go on to spontaneously resolve their HCV
infection. The remaining proportion (1− δ ) progress to the acute h1 infected class;
these individuals go on to develop chronic HCV infection. Of those PWID in the acute
h2 infected class, a proportion (α) go on to develop immunity to HCV re-infection
and the remaining (1−α) become susceptible to HCV re-infection (Farci et al., 1992;
Mehta et al., 2002; Micallef et al., 2007).
It has been well documented that recent initiates to injecting drug use exhibit dif-
ferent risk behaviour when compared to their more experienced counterparts (Cassin
et al., 1998; Hahn et al., 2002; Mathei et al., 2008). Furthermore, studies report a
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higher incidence of HCV infection (Roy et al., 2007; Mehta et al., 2011) and a greater
force of HCV infection (Sutton et al., 2006) amongst recent initiates to injecting drug
use. In an attempt to capture this heterogeneity in the injecting population, the model
stratified the population according to injecting career length - specifically two groups
for PWID with short (naive) and long (experienced) careers. Naive PWID move at
a per capita rate η to the experienced state, and retain their HCV infection status in
doing so.
2.2. Parameter estimation
Tables 1 and 2 summarise the baseline parameter estimates that were used in our
numerical simulations.
2.3. Acute and chronic HCV transmission probabilities through needle sharing (αh,αy)
We have assumed that αy = 2.5% based on observed data on HCV transmission
through needle-stick injury (Centre for Disease Control, 1997; Hutchinson et al., 2006).
In addition, we have assumed that the infectivity of, and probability of, HCV transmis-
sion through needle sharing associated with, the acute HCV infection state (αh) is
greater than that of the chronic HCV infection state (αy) as a result of a six to eight
week period of high viraemia that follows HCV infection (Simmonds et al., 1998). In
line with model fits obtained by Vickerman et al. (2007), we estimated that αh = 2.7αy.
This implies that αh = 6.8%.
2.4. Proportion that develop immunity to HCV re-infection (α)
Some, but not all, studies have shown a lower rate of HCV (re-)infection among
previously infected compared to previously uninfected PWID (Micallef et al., 2007;
Aitken et al., 2008; Corson et al., 2011). While this could be interpreted as immunity
to HCV re-infection, heterogeneity in HCV testing intervals, small sample sizes and
relatively short follow-up periods mean that it is difficult to quantify to what extent
PWID who have spontaneously resolved their infection develop immunity (Corson
et al., 2011; Vickerman et al., 2012). Due to the uncertainty in estimating this pa-
rameter, Vickerman et al. (2009) assumed that the proportion of PWID who become
immune could range between 0% and 100%. Here, we have conservatively estimated
that α = 0.25.
2.5. Duration of acute HCV infection (1/σ)
The acute phase of infection was taken to be the first six months after initial infec-
tion (Vickerman et al., 2007, 2009). Therefore, we estimated that (1/σ) = 0.5 years
or σ = 2 per year.
2.6. Proportion that resolve HCV infection (δ )
We estimated that δ = 0.26 based on a systematic review of longitudinal studies
involving 675 subjects (Micallef et al., 2006).
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2.7. Progression rate from the naive to the experienced injecting career group (η)
We define naive PWID to be those who have been injecting for five years or less
and experienced PWID to be those who have been injecting for more than five years,
consistent with the definition used for recent onset injectors in Scottish surveillance
reports (Needle Exchange Surveillance Initiative, 2010). Hence, 1/η = 5 years.
2.8. Proportion of PWID that are naive and experienced (pi0,pi1)
We assumed that 25% of the PWID population were naive and the remaining 75%
are experienced. This is consistent with current PWID in Glasgow, surveyed at services
providing injecting equipment in 2008-2009, where 23% (164/704) had commenced
injecting in the past five years (Needle Exchange Surveillance Initiative, 2010). In
addition, the size of the Glasgow PWID population has been relatively constant over
a number of years so we assume that our estimates for pi0 and pi1 are the equilibrium
values for these parameters. That is, pi0 = pi0∗ = 0.25 and pi1 = pi1∗ = 0.75.
2.9. Average length of injecting career (1/µ)
At equilibrium, the fraction of naive PWID in the population is given by µ/(µ +
η). Re-arranging this for µ and using our estimates for pi0∗ and η we see that µ =
0.06667 per PWID per year. This implies that the average length of injecting career is
approximately 15 years.
2.10. Probability of successful needle/syringe cleaning (φ )
We used data from a survey of PWID conducted in Glasgow during 1990-93 to
estimate φ (Hutchinson et al., 2000). Among the PWID who had reported injecting
with a used needle/syringe in the past six months, the majority (91%, 620/679) reported
they always cleaned their needles before use (155 bleach, 15 alcohol, 105 boiling water,
345 other); 24 mostly cleaned their needles (5 bleach, 3 boiling water, 16 other), 8
cleaned about half the time (2 bleach, 6 other), 11 cleaned occasionally (1 bleach, 10
other), 14 never cleaned and the remaining 2 said that they did not know.
We assumed that cleaning with bleach is 99.9% effective and alcohol is 85% effec-
tive at disinfecting needles/syringes infected with HCV (National Treatment Agency,
2009); other methods were assumed to be completely ineffective. We also assumed
that those individuals who mostly clean used needles prior to use will do this on aver-
age 87% of the time, those who clean about half the time will do so 50% of the time,
and those who occasionally clean will do so on average 13% of the time. We assumed
that the few individuals who reported that they did not know were completely inef-
fective at cleaning their needles before use. Applying these assumptions, we estimate
that 173 of 679 (25.5%) PWID, who reported sharing needles/syringes, would have
cleaned their needles successfully the last time they injected, providing an estimate for
φ of 0.255.
6
2.11. Number of needle/syringe sharing events (λ0,λ1)
Estimates for λ0 and λ1 were obtained from a survey of 704 current PWID (those
who reported injecting drugs in the six month period prior to interview) in Glasgow
during 2008-2009 (Needle Exchange Surveillance Initiative, 2010). We identified 162
naive and 535 experienced PWID who reported (a) the number of months spent inject-
ing, and (b) the frequency at which they shared needles/syringes (defined as injecting
with a needle/syringe that had already been used by someone else) in the one month
prior to interview. Of these, 10 (6%) naive and 47 (9%) experienced PWID reported
that they had shared needles/syringes at least once in the month prior to interview;
these 10 naive PWID reported sharing a total of 74 times (7.4 times on average each)
per month and the 47 experienced PWID reported sharing a total of 469 times (9.98
times on average each) per month. Naive PWID reported injecting for 8 months of the
year, thus we estimated that there were 592 (74×8) needle/syringe sharing events per
year among the 162 naive PWID. Similarly, experienced PWID reported injecting for
8.8 months of the year, and so there were an estimated 4,127 (469×8.8) needle/syringe
sharing events per year among the 535 experienced PWID. We therefore assumed that
the number of times in a year that a PWID shared needles/syringes was 3.7 (592/162)
for all those naive, and 7.7 (4,127/535) for all those experienced.
2.12. Number of paraphernalia sharing events (λ0F ,λ1F)
From a survey of 704 current PWID in Glasgow during 2008-2009 (Needle Ex-
change Surveillance Initiative, 2010), we identified 160 naive and 540 experienced
PWID of whom 61 (38%) naive and 183 (25%) experienced PWID reported that they
had shared injecting paraphernalia items at least once in the one month period prior to
interview. Since recent surveys do not quantify the frequency of paraphernalia shar-
ing in the period prior to interview, we assumed that the distribution of sharing events
amongst those who reported paraphernalia sharing in 2008-2009 was similar to that
obtained from a survey of 564 current PWID who reported sharing injecting parapher-
nalia in Glasgow in 2004. Allowing for months out of injecting (see above), we esti-
mated that there were 14,924 paraphernalia (3,936 filter, 5,436 cooker and 5,552 water)
sharing events per year for the 160 naive PWID and 62,180 paraphernalia (19,140 fil-
ter, 21,296 cooker, and 21,744 water) sharing events per year for the 540 experienced
PWID. Therefore, the average paraphernalia sharing rate for naive PWID (λ0F) was
93 sharing events per year and the paraphernalia sharing rate for experienced PWID
(λ1F) was 115 sharing events per year.
2.13. Fraction of needles/syringes and injecting paraphernalia sharing events that oc-
cur within injecting career groups (s00,s11,s00,s11) and across injecting career
groups (s01, s10, s01, s10)
No data sources were available to estimate the proportion of sharing that goes on
within injecting career groups (between naive PWID or between experienced PWID)
or across groups (between naive PWID and experienced PWID). We assumed that
PWID will tend to borrow equipment (needles/syringes or injecting paraphernalia)
from PWID in the same injecting career group. Hence we estimated that s00 = s00 =
s11 = s11 = 0.75 and s01 = s01 = s10 = s10 = 0.25.
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2.14. Simulations
Our aim was to determine the probability of HCV transmission through the sharing
of injecting paraphernalia (including filters, cookers and water).
Using the differential equation solver ode45 in MATLAB (2011) and the baseline
set of parameter estimates given in Tables 1 and 2, we modelled the prevalence of HCV
amongst PWID in Glasgow (a high prevalence setting). We report the transmission
probabilities that generated an endemic HCV prevalence consistent with that observed
from PWID surveyed in Glasgow during 2008-2009, in that the modelled prevalence
needed to lie within the 95% CI of the observed HCV antibody prevalence, i.e. between
67% and 73%, (Needle Exchange Surveillance Initiative, 2010).
In the baseline model, we assume that the probability of transmission relating to
the sharing of injecting paraphernalia with an individual with acute HCV infection was
2.7 times greater than that relating to sharing with an individual with chronic HCV, as
was assumed for the transmission probabilities associated with the sharing of nee-
dles/syringes. Hence, αhF = 2.7αyF and so the focus is on estimating the transmission
probability relating to the sharing of paraphernalia with a chronically infected individ-
ual. Note that the estimated transmission probabilities are for the collective sharing of
filters, cookers and water, not for each item individually.
To validate the model, we repeated our simulations in a low prevalence setting (Ta-
ble 1 in the supplementary material provides a summary of the parameter estimates
specific to the low prevalence setting). In this instance, we modelled the prevalence of
HCV amongst PWID in Lothian (the healthboard relating to Edinburgh city in Scot-
land) and we report the transmission probabilities that generated an endemic HCV
prevalence consistent with that observed from PWID surveyed in Lothian during 2008-
2009 (31%, 95% CI 25%-36%) (Needle Exchange Surveillance Initiative, 2010).
2.15. Sensitivity analysis
A sensitivity analysis was conducted for the high prevalence setting to investigate
how the central estimate for the transmission probability relating to the sharing of
paraphernalia with a chronically infected individual was affected by the uncertainty in
different parameter estimates.
Several one factor at a time sensitivity analyses were performed on the following
parameters: (i) the probability of successful needle/syringe cleaning (reduced to 0 and
increased to 0.5), (ii) the proportion that develop immunity to HCV re-infection (re-
duced to 0 and increased to 0.5), (iii) the acute HCV transmission probability through
needle sharing (reduced to 2.5% which assumes that there is no period of high viraemia
following HCV infection), (iv) the chronic HCV transmission probability through nee-
dle/syringe sharing (reduced to 1.5% and increased to 5% which are the lower and
upper estimates obtained from model fits to data from Rawalpindi, Pakistan (Vicker-
man et al., 2009)), (v) the proportion of PWID that are naive (increased to 0.3333), (vi)
the number of paraphernalia sharing events (reduced to 59 events per year for naive and
75 events per year for experienced PWID assuming HCV transmission does not occur
through the sharing of water), (vii) the number of needle/syringe sharing events (dou-
bled to 7.4 events per year for naive and 15.4 events per year for experienced PWID and
tripled to 11.1 events per year for naive and 23.1 events per year for experienced PWID
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to account for under-reporting), (viii) the swapping of the baseline needle/syringe (and
paraphernalia) sharing rates for naive and experienced PWID, and (ix) the fraction of
needle/syringe sharing events that occur within experience groups (reduced to 0.25
and increased to 1). It is worth noting that (a) the proportional relationship between
acute and chronic HCV infection is maintained when the transmission probability of
chronic HCV through needles/syringes is reduced to 1.5% and increased to 5%, and (b)
changes to these parameters affected the baseline estimates of other parameters (e.g.
the fraction of needle/syringe sharing events that occur across injecting career groups).
3. Results
3.1. Determining the probability of HCV transmission through the sharing of injecting
paraphernalia (including filters, cookers and water)
Figure 2 shows a plot of HCV prevalence (defined as those testing HCV antibody
positive, which is given by pi0x1+pi
0
h1
+pi0h2+pi
0
y +pi0z +pi1x1+pi
1
h1+pi
1
h2+pi
1
y +pi1z in our model) as
a function of αyF , the transmission probability of chronic HCV through paraphernalia
sharing.
For the high prevalence setting (Glasgow), we estimated that in order to achieve an
endemic HCV prevalence between 67% and 73%, we require the HCV transmission
probability through sharing paraphernalia with a chronically infected individual to be
between 0.166% and 0.225%, with a central estimate of 0.193%, approximately 13
times lower than the transmission probability associated with needle/syringe sharing
(αy = 2.5%). These estimates imply that the HCV transmission probability through
the sharing of paraphernalia with an acutely infected individual is between 0.448%
and 0.608%.
For the low prevalence setting, we estimated that in order to achieve an endemic
HCV prevalence of 31% (and between 25% and 36%) we require the HCV transmis-
sion probability through sharing paraphernalia with a chronically infected individual
to be 0.170% (and between 0.157% and 0.183%), approximately 15 times lower than
the transmission probability associated with needle/syringe sharing. These estimates
imply that the HCV transmission probability through sharing paraphernalia with an
acutely infected individual is between 0.424% and 0.494%.
3.2. Sensitivity analysis
The results of our sensitivity analyses are presented in Figure 3. Three scenarios
lead to changes in the HCV transmission probability (through paraphernalia sharing)
by a margin of more than 0.09%. First, reducing the number of paraphernalia sharing
events per year by excluding the water sharing events results in an increase in our es-
timate for the transmission probability of chronic HCV through paraphernalia sharing
(from 0.193% to 0.301%). Second, doubling to tripling the number of needle/syringe
sharing events results in our estimate decreasing from 0.193% to 0.10% and 0.008%,
respectively. Third, increasing the transmission probability of chronic HCV through
needles/syringes to its upper estimate of 5% results in our estimate decreasing from
0.193% to 0.10%.
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3.3. Proportion of infections attributable to paraphernalia sharing
To estimate the proportion of infections attributable to paraphernalia sharing, we
used the central estimate for the transmission probability relating to the sharing of
paraphernalia with a chronically infected individual to calculate the equilibrium force
of infection (given by (13) in the supplementary material).
Several scenarios were considered: relating to the baseline parameters for the high
and low prevalence settings (with αy f = 0.193%, and 0.170%, respectively); and in the
high prevalence setting, reducing the number of paraphernalia sharing events per year
by excluding the water sharing events (with αy f = 0.301%), and doubling and tripling
the needle/syringe sharing rates (with αy f = 0.10% and 0.008%, respectively).
Our results showed that approximately 62% of infections in the high prevalence
setting and 73% of infections in the low prevalence setting can be attributed to para-
phernalia sharing. Furthermore, in the high prevalence setting, excluding water shar-
ing events has little impact on the proportion of infections attributable to paraphernalia
sharing (63% compared to 62%). However, doubling the needle/syringe sharing rates
halves the proportion of infections attributable to paraphernalia sharing (30% com-
pared to 62%), while tripling the needle/syringe sharing rates reduces this proportion
even further (2% compared to 62%).
4. Conclusions and discussion
Laboratory studies and epidemiological surveys have suggested that the sharing
of injecting paraphernalia (such as cookers, filters and water) may contribute to the
spread of HCV amongst PWID (Crofts et al., 2000; De et al., 2008; Pouget et al.,
2012). PWID in Scotland have reported much higher levels of paraphernalia shar-
ing than needle/syringe sharing and it is possible that the former may explain the high
HCV prevalence that is observed in this population (Needle Exchange Surveillance Ini-
tiative, 2010). With this in mind, recently developed Scottish guidelines for injecting
equipment provision have recommended an increase in the provision of paraphernalia
items (cookers, filters and water) so that every injector has access to a sterile set of
equipment for each injection (Scottish Government, 2010). Given that the resources
required to meet the guidelines are likely to be substantial, it is important to quantify
the role that the sharing of these items plays in disease transmission.
Here we have developed a dynamic mathematical model that allowed HCV trans-
mission to occur through the sharing of needles/syringes and other injecting parapher-
nalia (defined as cookers, filters and water). Using parameter estimates obtained from
surveys of Scottish PWID, we simulated the behaviour of the model and estimated the
transmission probability of HCV through the sharing of injecting paraphernalia. Our
numerical simulations implied that, provided that the reported needle/syringe sharing
rates are accurate, the probability of HCV transmission through sharing paraphernalia
(either cookers, filters or water) with a chronically infected individual was approxi-
mately 0.19%; this estimate was approximately 13 times lower than the transmission
probability associated with needle/syringe sharing (2.5%). This result was corrobo-
rated by numerical simulations performed with data on PWID from Lothian (a low
10
prevalence setting) which generated a transmission probability estimate of approxi-
mately 0.17%. Furthermore, we estimated that approximately 62% and 73% of infec-
tions in the high and low prevalence settings, respectively, were attributable to para-
phernalia sharing (assuming the baseline needle/syringe sharing rates for both settings
are correct). A recent analysis of Scottish survey data by Palmateer et al. (2012) found
that amongst PWID who did not report needle/syringe sharing, the sharing of filters
and spoons was significantly associated with recent HCV infection, but the sharing
of water was not. Therefore, we reduced the number of paraphernalia sharing events
by excluding water sharing and found that this increased our estimate from 0.19%
to 0.30% per paraphernalia sharing event with a chronically infected individual; the
latter estimate was 8 times lower than the transmission probability associated with
needle/syringe sharing.
These results suggest that the sharing of injecting paraphernalia could potentially
contribute to the spread of HCV amongst PWID. These results are supported by Mathei
et al. (2006) whose simulation study considered HCV transmission through parapher-
nalia sharing and examined how sharing behaviours affect the force of infection. Their
results suggested that PWID who reported the sharing of injecting paraphernalia expe-
rienced a greater force of infection and had a higher long term HCV prevalence than
those who did not report the sharing of injecting paraphernalia.
A recent meta-analysis by Pouget et al. (2012) suggested that the risk of HCV
infection through shared drug preparation equipment was similar to that of shared sy-
ringes. This is based on the finding that the pooled risk ratio of HCV seroconversion
was 1.94 (95% CI 1.53-2.46) for those who had shared a syringe and 2.24 (95% CI
1.28-3.93) for those who had shared drug preparation equipment. The authors did not
present information on the number of shared injection episodes in their review, most
likely because this was also not available in the primary articles, and therefore did
not examine differences in risk of HCV according to the number of events involving
shared needles/syringes and other paraphernalia. In our model, we were able to build
in the number of sharing events for each item of injection equipment; in doing so, we
highlight that the number of paraphernalia sharing events is far in excess of that for
needles/syringes (that is, 17 times more paraphernalia, compared to needle/syringe,
sharing events per PWID per year in Glasgow). Allowing for these data, we illustrate
that the transmission risk associated with each paraphernalia sharing event is therefore
many times lower than that of a needle/syringe sharing event.
To estimate the number of needle/syringe sharing events for naive and experi-
enced PWID in Glasgow, we used needle/syringe sharing frequency data extracted
from the 2008-2009 survey of PWID in Glasgow. The estimates obtained from this
data (3.7 and 7.7 for naive and experienced PWID, respectively) were found to be:
(a) consistent with the needle/syringe sharing frequency reported by Glasgow PWID
in surveys since conducted in 2010 and 2011-2012, and (b) in line with low levels
of needle/syringe sharing in other countries that have implemented substantial inject-
ing equipment programmes such as England and Australia (The Kirby Institute, 2011;
Health Protection Agency, 2012). Nevertheless, it is entirely possible that PWID
under-report their needle/syringe sharing risk behaviour. Sensitivity analyses, which
assumed that needle/syringe sharing rates were double that reported in Glasgow during
11
2008-2009, showed that the model required a much smaller estimate for the probability
of HCV transmission through paraphernalia sharing to produce prevalence estimates
that fitted with that observed amongst Glasgow PWID in 2008-2009 (0.1% compared
to 0.19%). This potential bias would mean that we have under-estimated the number
of needle/syringe sharing events and over-estimated the risk of HCV infection through
paraphernalia sharing. Given that our estimates are sensitive to the number of nee-
dle/syringe sharing events, it is important that we understand to what extent PWID
under-report their needle/syringe sharing so that we can gain a more accurate under-
standing of the potential risks associated with the sharing of injecting paraphernalia.
It is worth noting that our baseline model applied a higher number of sharing
events (needle/syringe and paraphernalia) to experienced PWID than naive PWID.
Although this may seem counter intuitive, our sensitivity analyses showed that this
discrepancy did not invalidate our results: swapping the baseline naive and experi-
enced needle/syringe (and paraphernalia) sharing rates reduced our estimate by 0.02%
to 0.17%.
In our analysis we have assumed that the transmission probability of chronic HCV
through needles/syringes (αy) is 2.5% (Centre for Disease Control, 1997; Hutchinson
et al., 2006), while more generally, estimates obtained from model fits to data from
Pakistan suggest that αy lies between 1.5% and 5% (Vickerman et al., 2009). Our sen-
sitivity analyses showed that an increase in αy would almost halve the risk of infection
associated with paraphernalia sharing; the probability of HCV transmission through
sharing paraphernalia with a chronically infected individual decreased approximately
0.19% to 0.1% as αy was increased from 2.5% to 5%. Quantifying the risks associated
with needle/syringe sharing is thus essential to fully appreciate the risks associated
with paraphernalia sharing.
Although this analysis examines the risks associated with the sharing of filters,
cookers and water, there is some uncertainty as to which items of injecting parapher-
nalia should be considered as potential HCV transmission sources. For example, Crofts
et al. (2000) found that 40% (2/5) of filters tested had detectable levels of HCV RNA
which suggests that filters could be a viable source of HCV infection. In contrast
Thibault et al. (2011) did not detect HCV RNA in the pool of ten filters collected from
PWID who reported that they were infected with HCV. Although the authors mention
that no firm conclusions can be drawn on the potential risk of contamination though
the sharing of filters, this discrepancy highlights the need for more studies designed to
investigate the risks associated with shared paraphernalia.
As with all modelling studies there are a number of limitations. The deterministic
nature of our model does not allow us to incorporate the random variability in nee-
dle/syringe sharing rates and paraphernalia sharing rates. That said, we do allow for
a level of heterogeneity in these sharing rates by modelling the spread of HCV infec-
tion amongst naive and experienced PWID, each with different risk behaviours. It is
reasonable to consider that the transmission probability of HCV through one parapher-
nalia item (e.g. filters) will be different from the other items (e.g. cookers and water).
Our simulations were unable to generate separate transmission probabilities for filters,
cookers and water. Therefore, we are unable to determine whether one particular item
of equipment poses a greater risk than the others. When calculating the parameter esti-
12
mate for φ (the probability of cleaning needles/syringes) we found that recent surveys
of PWID in Glasgow did not quantify the frequency of needle/syringe cleaning in the
period prior to interview. The use of cleaning data from the early 1990s may result
in an under-estimation of the level of preventative cleaning that is ongoing within the
Glasgow PWID population which would in turn lead to our model under-estimating
the risks associated with paraphernalia sharing. Furthermore, we conservatively as-
sumed that only two needle/cleaning methods (bleach and alcohol) were effective at
sterilising HCV infected needles/syringes. Studies by Abdala et al. (2001, 2004) have
suggested that several methods may have some efficacy when it comes to inactivating
blood-borne infections and thus our estimate for φ may be further under-estimated.
However, sensitivity analyses showed that our model was not overly sensitive to this
parameter. Finally, our modelling work does not consider non-injecting transmission
routes for HCV (such as tattooing and sexual transmission). If these transmission
routes were to be incorporated, it is possible that our estimate for injecting parapher-
nalia transmission would be somewhat reduced.
In conclusion, our results suggest that the sharing of injecting paraphernalia (such
as cookers, water and filters) could be contributing to the growing healthcare burden
associated with HCV. Given that PWID are reporting that they share injecting para-
phernalia at a much greater frequency than with which they share needles/syringes, it
is imperative that every effort be made to establish (a) the contribution that parapher-
nalia sharing is making to the ongoing spread of HCV, and (b) the effectiveness of
services providing sterile paraphernalia in preventing infection. It may be difficult to
determine from observational studies the risk of HCV transmission for each parapher-
nalia item, given the extent to which these behaviours co-exist. Nevertheless, a natural
experiment is underway in Scotland - as a result of extra investment from Govern-
ment (Scottish Government, 2008) and new national guidelines (Scottish Government,
2010) - which will inform on whether the increased provision of sterile paraphernalia
(especially filters and cookers) is associated with a reduced risk of HCV transmission
among PWID.
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